




2021

ANNUAL REPORT

amfAR,
The Foundation for
AIDS Research

amfAR

MAKING AIDS HISTORY

OUR MISSION

amfAR, The Foundation
for AIDS Research, is
dedicated to ending the
global AIDS epidemic
through innovative research.

CONTENTS

Forging Ahead, Leading the Way	01
Research	01
Public Policy	04
TREAT Asia	06
Public Information	09
Grants, Fellowships, and Awards	11
Research Grants, Fellowships, and Awards	11
TREAT Asia Grants and Awards	12
Public Policy Grants and Awards	14
Financials	15
Leadership and Advisory Committees	17
Board of Trustees	17
Scientific Advisory Committee	17
Program Advisory Council	21
Management Group	21

FROM THE CO-CHAIRS



Dear Friend of amfAR,

We are pleased to update you with this overview of amfAR's activities and achievements in 2021.

The narrative section of this annual report speaks to the tremendous breadth of the Foundation's work and its far-reaching impact on people and communities in the U.S. and around the world. All of this is made possible by the depth of knowledge and experience, and the dedication, that everyone at amfAR brings to the Foundation's mission.

Of course, none of this would be possible without *you*—our generous donors. We are profoundly grateful to all who contribute in different ways, at different levels, and from different parts of the world. We are all bound by a shared desire to bring the global HIV/AIDS epidemic to an end. The key to achieving that goal remains the innovative research that has fueled our progress in the fight against AIDS for the past 40 years.

With 38 million people living with HIV/AIDS worldwide, we continue to push forward with the utmost urgency, and we hope we can count on your continued support. In an age of seemingly infinite global crises and ever-growing demand for precious charitable resources, your support is more important—and more greatly appreciated—than ever.



Kevin McClatchy
Co-Chair of the Board



T. Ryan Greenawalt
Co-Chair of the Board

FORGING AHEAD, LEADING THE WAY



amfAR Mathilde Krim Fellow Ujjwal Rathore, Ph.D.

RESEARCH

Decades of HIV research provided a solid foundation for researchers to develop coronavirus vaccines at breakneck speed and see them distributed throughout 2021. With this easing of the threat posed by COVID-19, the research community was able to return to previous concerns with renewed vigor. HIV researchers were no exception, and amfAR helped many of these scientists forge ahead, supporting 30 research teams involving 167 scientists.

ART-Free Control of HIV

Some of the exciting work that amfAR has supported in 2021 focused on antiretroviral therapy (ART)-free and post-treatment control of HIV.

The “Esperanza Patient”

Researchers, including several amfAR grantees, reported on a woman who appears to be a new case of a spontaneous HIV cure. Published in *The Annals of Internal Medicine*, the report states that an exhaustive search of 1.5 billion of the woman’s cells failed to turn up a single intact virus capable of replicating. Dubbed the “Esperanza patient” after her home town in Argentina (meaning “hope”), she is what is known as an elite controller, an individual living with HIV who is able to

control their virus without therapy; Loreen Willenberg, the “San Francisco patient,” is believed to be the first known case.

HIV Controller Think Tank

In December 2021, amfAR convened a think tank of 15 researchers to address a vital question: Can long-term treatment lead to ART-free control of HIV? The assembled researchers, which included Drs. Xu Yu, of the Ragon Institute of Massachusetts General Hospital, MIT and Harvard, and Mathias Lichterfeld, of Brigham and Women’s Hospital in Boston, thoroughly investigated the phenomenon of elite controllers in an effort to understand the mechanisms that enable them to naturally suppress HIV.

Scientists at the think tank presented what is known about the ability to control HIV without ART in a range of people living with HIV (PLWH), including elite controllers and post-treatment controllers—people who took ART for a number of years then stopped without experiencing viral rebound. Coming out of the think tank, amfAR is currently investigating the exciting possibility that some people who have taken ART for many years may, unbeknownst to them, have cleared the virus and no longer need treatment.

Why Do Some Elite Controllers Stop Controlling HIV?

Prior research linked HIV control to robust functioning of CD8+ killer T cells. In a new study of CD8+ T cells, Dr. Steven Deeks of the amfAR Institute for HIV Cure Research and colleagues

examined serial blood samples from 34 HIV controllers, half of whom maintained such control for at least two years and half of whom lost it. The difference between the two groups related to genes responsible for the proliferation of the toxic killing molecules that CD8+ T cells produce. In addition, CD8 cells taken from lymph nodes showed poor functioning in the aborted control vs. durable control groups. Thus, durable HIV control depends on the maintenance of HIV-specific CD8+ T cell functionality.

Supporting Cutting-Edge Research

Target Grants

Next Generation HIV Cure Intervention

In November 2020, amfAR awarded funding to veteran HIV researcher Dr. Jerome Zack, of the University of California, Los Angeles, who is employing a new intervention based on a promising cancer therapy approach to attempt to rid the body of the persistent reservoir of HIV—the ultimate barrier to a cure. Dr. Zack and colleagues are using both normal and engineered natural killer (NK) cells in an effort to eliminate cells harboring reservoir virus from the body.

A Trio of Gene Therapy Approaches

In June 2021 amfAR awarded approximately \$600,000 in new funding to researchers pioneering gene therapy approaches to target and eliminate the HIV reservoir with far greater specificity than is currently possible.

Dr. Todd Allen, of the Ragon Institute of MGH, MIT and Harvard, and colleagues have identified a group of antibodies they have called broadly functional antibodies (bFABs), which are adept at binding to infected cells and flagging them for destruction by other components of the immune system such as NK cells. Dr. Allen and his team aim to test the bFABs alone and in combination with genetically engineered CAR T cells with enhanced ability to kill cells infected by HIV that his team has already designed.




Steven Deeks, M.D.

CAR T cells have proven highly effective against certain blood cancers, but less so against HIV—partly because they are susceptible to infection and destruction by the virus. The immense genetic variability among viruses even within an individual with HIV also presents a formidable challenge. A team led by Dr. Anastasios Karadimitris, of Imperial College, London,

plans to address both issues by using cells that combine the characteristics of naturally occurring NK cells and T cells as the basis for their CAR cell therapy. These invariant (i) NKT cells do not carry the CD4 protein on their surface and thus are resistant to HIV infection. To address genetic breadth, the researchers will use combinations of up to three targeting strategies.

CRISPR/Cas gene-editing technology has shown breakthrough potential for treating a range of medical conditions. In the field of HIV cure research, being able to excise the virus wherever it has inserted itself into host DNA is a challenging task. Across the genome there are very tightly wound regions that limit access to the DNA and have proven difficult for CRISPR/Cas to penetrate effectively. Recent evidence shows that HIV sometimes integrates into these “gene deserts.”



Jori Symons, Ph.D.

Dr. Jori Symons, of University Medical Center Utrecht, and colleagues plan to test whether this explains the resistance of some viruses to excision by CRISPR/Cas. They aim to increase the gene-editing tool's effectiveness with drugs that open up and expose the DNA.

COVID-19 Grants

In April 2020, amfAR established the amfAR Fund to Fight COVID-19 in order to respond to the novel coronavirus via research. In July 2021, amfAR awarded approximately \$700,000 to researchers trying to answer two key questions at the intersection of HIV and COVID-19.

Researchers know that people who have cleared COVID-19 infection may go on to experience debilitating long-term symptoms, but what are the risks for those COVID “long haulers” who are living with HIV? Dr. Annukka Antar, of Johns Hopkins University, and Dr. Michael Peluso, of the University of California, San Francisco, are comparing this phenomenon across three groups of study participants. In the study, PLWH who have survived COVID-19 are compared to PLWH with no history of

COVID and survivors who are HIV-negative. Using a mobile phlebotomy service, Drs. Antar and Peluso also plan to collect blood samples and study vital signs to aid in understanding the biological underpinnings of long-term COVID.

Knowing that coronavirus infection is associated with strong immune responses, what, if any, impact does SARS-CoV-2 have on the size of the HIV reservoir? Dr. Mathias Lichterfeld and colleagues aim to assess the size and nature of the reservoir in PLWH before and after coronavirus infection. The researchers are comparing the percentage of cells that are HIV-infected with samples stored before the COVID-19 pandemic. They are also looking for any effect of the site of HIV integration within the human DNA on reservoir size and assessing the likelihood of activation by COVID-associated immune responses. Understanding these changes will help inform future HIV curative interventions.

Among the grants amfAR has awarded for COVID-19 research, a study by researchers at the University of Montreal generated four scientific papers, including one in the high-impact journal *Nature Medicine*. Tapping into the Quebec COVID-19 Biobank, a large repository of biological samples from COVID patients, the researchers were able to identify a protein called OAS1 that appears to have a protective effect against COVID-19. The next step will be to look for existing drugs that increase OAS1 levels and might therefore form the basis of an effective treatment.

Mathilde Krim Fellowships

Each year, Mathilde Krim Fellowships in Biomedical Research are awarded to early-career scientists who show promise in the field of HIV research. In March 2021, amfAR announced the latest recipients, who are awarded approximately \$150,000 over two years:

Dr. Aleksandar Antanasijevic, of The Scripps Research Institute, La Jolla, CA, is using a sophisticated imaging technology called cryoEMPEM to address the obstacles that make developing an HIV vaccine so challenging.

Dr. Ujjwal Rathore, of the Gladstone Institutes, San Francisco, CA, is using a newly developed CRISPR/Cas9 gene-editing system to understand how human cells help maintain HIV latency, a main barrier to a cure.

A 2019 Krim Fellow, Dr. Maolin Lu, of University of Texas Health Science Center at Tyler, was awarded a second phase grant of \$80,000 in June 2021. Shortly before receiving the initial Krim Fellowship, Dr. Lu published a groundbreaking study in *Nature* that revised what we knew about the behavior of HIV surface proteins and upended the HIV vaccine field. Dr. Lu's amfAR-funded study built on her own cutting-edge research.

Countdown to a Cure for AIDS

In 2015, amfAR announced a multimillion-dollar investment strategy to support its Countdown to a Cure for AIDS (C2C) initiative, which was aimed at developing the scientific basis for a cure. Established with a \$20 million grant over five years to the University of California, San Francisco, the amfAR Institute for HIV Cure Research was the cornerstone of C2C. The strategy was designed to provide support to any scientist or team of investigators for any research idea with the potential to advance the search for a cure, at any stage of its development. Since launching C2C, amfAR has awarded 89 Countdown grants totaling more than \$50 million to support research conducted by 307 scientists working at 103 institutions in 16 countries.

Ongoing research includes a potentially groundbreaking clinical trial, led by Dr. Steven Deeks, principal investigator at the amfAR Institute for Cure Research, that is testing a combination of agents in an effort to induce post-treatment control in people living with HIV. The complex, multi-stage trial is the culmination of four years of work by teams of researchers at the Institute.


Sharing Knowledge

Published Research

amfAR is a leading voice in the scientific conversation pertaining to HIV, as evidenced by the multitude of amfAR-funded research studies published in peer-reviewed journals. In FY2021, 45 scientific publications resulted from amfAR-funded research. Examples include:

Predicting Post-Treatment Control of HIV

Eradicating HIV depends in part on finding a biomarker that can predict the likelihood of HIV remission after treatment is stopped. With the help of machine-learning tools, amfAR-funded researchers led by Dr. Mohamed Abdel-Mohsen developed blood-based biomarkers that were able to predict the probability of viral rebound with almost 98% accuracy. The study, published in the influential journal *Nature Communications*, could help fill a critical gap in the HIV cure research field.



Mohamed Abdel-Mohsen, Ph.D.

CAR T Cells for HIV Cure

CAR T cells, which have revolutionized the treatment of certain leukemias and lymphomas, are the focus of amfAR grantees Drs. Scott Kitchen and Jerome Zack, who overcame two major challenges to the use of this therapy to kill reservoir cells and cure HIV. As described in *PLoS Pathogens*, they gene-edited stem cells to

improve the long-term survival of the resulting CAR T cells and used a gene modification that not only protects the cells from HIV infection, but also improves their conversion from stem cells to CAR T cells. The researchers also reported in *JCI Insight* that these cells traffic to tissue regions where reservoirs are most concentrated.

Meet the Scientists

In December 2020, in honor of World AIDS Day, amfAR held a virtual convening of *Meet the Scientists*. Dr. Rowena Johnston, vice president and director of research, moderated a stimulating discussion with amfAR grantees Dr. Timothy Schacker, of University of Minnesota Medical School, and Dr. Jerome Zack, of University of California, Los Angeles.

The event focused on state-of-the-art research on NK cells, the subject of growing interest as part of a cure for HIV. Dr. Schacker completed an amfAR project exploring transplantation of NK cells between close relatives as a means of reducing the reservoir in the HIV-positive recipient. And amfAR recently awarded funding to Dr. Zack, who is comparing the ability of normal versus engineered NK cells to eliminate cells harboring reservoir virus from the body.

PUBLIC POLICY

In 2021, Greg Millett, vice president and director of public policy, marked the 40th anniversary of the first reports of what would come to be known as AIDS by taking part in a virtual webinar and conversation with senior federal officials and community leaders. Although noting that progress has been made, he reminded viewers of the work that still needs to be done, especially in light of health disparities revealed by the COVID-19 pandemic.

In this context, amfAR continued its data-driven advocacy of rational and compassionate HIV/AIDS-related public policy by engaging in efforts to secure necessary increases in funding for HIV/AIDS research and global HIV/AIDS programs, expand access to treatment and care for marginalized populations, advocate harm reduction policies aimed at reducing the transmission of HIV and hepatitis C (HCV) among people who inject drugs, and protect the civil rights of all people affected by or vulnerable to HIV/AIDS.

Ending the HIV Epidemic in the U.S.

Promoting an Evidence-Based Response

Throughout the year, the amfAR policy team worked closely with members of the Biden administration, the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the Department of Health and Human Services



amfAR VP and Director of Public Policy Greg Millett

(HHS) to promote an evidenced-based response to the U.S. HIV epidemic. This included advocacy to reestablish the White House Office of National AIDS Policy.

Policy staff were invited to deliver a presentation to the Presidential Advisory Council on HIV/AIDS and worked with other domestic advocates to discuss recognition of the 40th anniversary of the HIV pandemic with the Biden administration. amfAR's policy office worked to secure \$200 million in additional funding above the level of the President's Budget Request for HIV research at the NIH in the FY2022 House appropriations bill. Policy staff worked closely with the CDC and Community Education Group to co-host a meeting on syndemics and the HIV response. They also participated and provided key insights in the 2021 CDC Policy Leaders Working Group for state policy priorities.

In addition, the policy office engaged with the development and rollout of the updated National HIV/AIDS Strategy, including discussions with the White House, and amfAR's policy analyses were cited in the newly released Strategy.

Striving for Health Equity

In 2021, amfAR continued to highlight the impact of COVID-19 on the HIV response both domestically and globally, and the inequitable domestic impact of COVID-19. Policy staff participated in the COVID-19 Health Equity Task Force stakeholder briefings with the Office of Public Engagement and in several meetings of the NIH COVID-19 Prevention Trials Network to discuss vaccine distribution. Policy staff discussed COVID-19 data deficiencies and recommendations for the new administration with partner organizations, and delivered presentations on the intersections of COVID-19 with HIV, LGBT communities, and racial disparities.



Understanding HIV and the Opioid Epidemic

amfAR maintains an important and widely used resource on HIV and the opioid epidemic: the Opioid & Health Indicators Database (opioid.amfar.org). This free web platform is designed to support lawmakers, communities, and advocates in making informed decisions about the opioid epidemic and its impact on HIV and hepatitis C. The site provides data on new HIV and hepatitis C infections, opioid use and overdose death rates, and the availability of services like drug treatment programs and syringe exchange services.

In 2021 amfAR staff worked with HHS on the Ending the HIV Epidemic Plan and Opioid and Infectious Disease Programs. Policy staff also participated in the Region 5 Opioid Task Force of the Substance Abuse and Mental Health Services Administration (SAMHSA).

Addressing the Global Epidemic

Expanding Global Health Access

The amfAR policy office maintains an active role in global advocacy and policy initiatives including attending PEPFAR Country Operational Planning meetings, the Global Fund partnership forum, and the UN High-Level Meetings on HIV/AIDS. Policy staff engage in advocacy with House and Senate appropriations committees to secure strong global HIV budgets and closely track and respond to new global health policies. Additionally, the policy office plays a key role as a technical assistance provider for in-country community-led monitoring efforts in seven countries. In this role, amfAR engages with local activists and data collection teams to ensure high-quality data are produced for HIV service quality monitoring and advocacy efforts.

Throughout 2021 amfAR staff published several studies in academic journals with far-reaching policy implications.

The role of contraception in preventing HIV-positive births: global estimates and projections, BMC Public Health. This research quantifies the importance of contraception for HIV prevention and has been used for global advocacy on HIV/family planning integration.


Current allocations and target apportionment for HIV testing and treatment services for marginalized populations: characterizing PEPFAR investment and strategy, Journal of the International AIDS Society. This research has been used to equip global HIV advocates with in-depth knowledge of PEPFAR's investment strategy for key and marginalized populations.

In 2021 amfAR staff partnered with trans-led organization GATE to design and implement research on best practices in trans inclusion in national HIV strategic plans (NSPs). This work included research on current levels of trans inclusion in NSPs as well as local advocacy in five target countries to increase trans inclusion. International stakeholders from UNAIDS and the Global Fund were involved in project planning and have committed to using project data.

The results of the study were depicted in a series of infographics showing how transgender people are often neglected, and sometimes excluded altogether, in the key sections of NSPs.



Policy staff participated in meetings of the NIH COVID-19 Prevention Trials Network to discuss vaccine distribution.



Another amfAR infographic (above) shows how the COVID pandemic has necessitated costly program adaptations in order to maintain global gains against HIV by PEPFAR and the Global Fund. As a result, PEPFAR faces a \$1 billion budget shortfall, potentially resulting in thousands of HIV treatment disruptions, new infections, and preventable AIDS-related deaths.

Empowerment Through Data

In addition to the Opioid & Health Indicators Database referenced above, amfAR maintains a suite of free, interactive databases that focus on the global HIV response. These are an invaluable source of data for individuals and organizations working to secure HIV-related funding and tailor programs appropriately.

PEPFAR Monitoring, Evaluation, and Reporting (MER) Database (mer.amfar.org): Launched in December 2018, the MER database enables policymakers, public health officials, advocates, and other stakeholders to access a wide range of programmatic PEPFAR data and includes downloadable PDFs, maps, data visualizations, and district-level data.

PEPFAR Country/Regional Operational Plans Database (copsdata.amfar.org): A complement to the MER Database, this database highlights planned funding by program area, country, and organization for each year that has been publicly released. The database is designed to help PEPFAR in its efforts to increase data transparency and general participation in the planning process.

Key Populations and Key Population Investment Fund (KPIF) Data Project (kpdata.amfar.org): Launched in 2021, the Data Project brings together available data on Key Populations demographics, epidemiology, funding, and programming from UNAIDS, PEPFAR, and the Global Fund. This resource includes country factsheets showing how funding has evolved over time, and, where possible, identifies who is responsible for implementing KP programming in the PEPFAR program. This project complements existing work in the MER and COPs databases and will be a key tool for KP advocates going forward.

11th IAS Conference on HIV Science and Other Conferences

amfAR's policy office participated in the 11th IAS Conference on HIV Science—the premier global meeting for HIV research and how it might be applied to policy and practice. Delegates came together virtually to hear about and discuss the latest HIV research findings and policy issues, and intersections with COVID-19. At the conference amfAR staff presented new data on the PEPFAR Key Populations Investment Fund. They also co-authored a poster presentation showcasing the use of community-led monitoring data in South Africa.

Public Policy Director Greg Millett delivered a presentation during CROI (Conference on Retroviruses and Opportunistic Infections) regarding PrEP access for key populations globally. Millett also participated in several planning meetings for IAPAC's global HIV meeting in Lisbon, Portugal, in November 2021.

TREAT ASIA

The landscape of HIV/AIDS in the Asia-Pacific region is a patchwork quilt of progress made and progress stalled. The region has struggled to keep up with global efforts to end AIDS as a public health threat by 2030. While countries like Cambodia and Thailand are close to reaching treatment targets set by UNAIDS, only 60% of all people living with HIV in the Asia-Pacific region are on lifesaving antiretroviral therapy. And with high burdens of hepatitis B and C and tuberculosis, and the emergence of COVID-19, there is increasing local competition for limited health resources.

For 20 years, amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) has been working with partners across the Asia-Pacific region to expand access to treatment for HIV and related conditions such as hepatitis C and improve standards of care. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced 28 publications in peer-reviewed medical journals in FY2021.

In 2021, TREAT Asia received a five-year \$14.5 million grant from the NIH. The grant represents the program's fourth successive



(L-R) Dr. Man-Po Lee (Hong Kong), Ms. Tor Petersen and Dr. Annette Sohn of TREAT Asia, Dr. Nguyen Van Kinh (Vietnam), Dr. Bui Vu Huy (Vietnam), and Dr. Jeremy Ross of TREAT Asia.

round of funding for a partnership between TREAT Asia and the Kirby Institute at the University of New South Wales (UNSW), Sydney, Australia.

Improving Health Through Information

By creating and maintaining databases of vital information about the Asia-Pacific region, TREAT Asia seeks to support clinicians and researchers in order to create better health outcomes for people living with and at risk for HIV.

International epidemiology Databases to Evaluate AIDS

(IeDEA): TREAT Asia manages the Asia-Pacific section of this global research consortium established by the U.S. National Institute of Allergy and Infectious Diseases. IeDEA Asia-Pacific is comprised of a network of over 50 clinical centers and research partners that studies the treatment outcomes of people living with HIV.

TREAT Asia HIV Observational Database (TAHOD): TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data from more than 10,000 patients at 21 clinical sites in 12 countries. The information gathered in the database informs the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. Launched in 2014, TAHOD Low-Intensity Transfer (TAHOD-LITE) contains data from over 51,000 HIV-positive patients across 11

TREAT Asia network sites. As an extension of TAHOD, TAHOD-LITE aims to increase the scope of adult data collection by gathering a subset of core variables from the entire cohort of HIV-positive patients who have sought care at selected TAHOD sites.

TREAT Asia Pediatric HIV Observational Database

(TApHOD): Set up by TREAT Asia in 2006 and modeled after the adult database, TApHOD is a regional pediatric HIV study that includes data from more than 7,400 children and adolescents at 17 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.

Integrating HIV, Mental Health, and Implementation Science Research

In 2019, the NIH awarded a five-year, \$1.4 million grant to TREAT Asia and Columbia University to establish an innovative platform for integrating HIV, mental health, and implementation science research in the Asia-Pacific region. The objective of the CHIMERA program (**C**apacity development for **H**IV and **m**ental health **r**esearch in **A**sia) is to address the dual and interlinked burdens of HIV and mental health. Co-led by Principal Investigators Dr. Annette Sohn, amfAR vice president and director of TREAT Asia, and Dr. Milton Wainberg, professor of clinical psychiatry at Columbia University and the New York State Psychiatric Institute, the program aims to build a team within the Asia-Pacific with the capacity to lead regional HIV-mental health-implementation

science research that will inform public health policy and improve the quality of clinical care for people living with HIV.

CHIMERA, which is nested within leDEA Asia-Pacific, creates the opportunity to bring together stellar training faculty from academic centers and public health and development agencies within the region and across the world, and builds on existing NIH-funded mental health research being conducted through leDEA Asia-Pacific.

In December 2020, a final workshop for the first class of CHIMERA fellows was held remotely, covering implementation research methods, responsible conduct of research, policy development, stigma, community participation in research, and scientific writing. Six of eight Class I fellows began implementation of their pilot research studies in 2021. A second class of eight fellows attended program orientation in April 2021.

Responding to COVID-19

TREAT Asia is collaborating with the Institute of HIV Research and Innovation, Thai Red Cross AIDS Research Center laboratory, and the NIH Vaccine Research Center (VRC) to conduct SARS-CoV-2 serologic assays of Thai adults taking and not taking antiretroviral drugs for pre-exposure prophylaxis and treatment of HIV. In September 2020, more than 1,800 samples were sent to the NIH. In 2021 the VRC proposed an expansion of the study collaboration to follow longitudinal serologic patterns and assess for infections with other viral pathogens. A draft protocol was developed and shared with the working group in September 2021.

In 2021 TREAT Asia launched www.covid19asiainfo.org, an important new online source of information on COVID vaccines and therapeutics specific to the Asia-Pacific region.

Throughout the year, TREAT Asia continued to participate in meetings held virtually with organizations and community members from countries throughout the Asia-Pacific region to navigate the impacts of COVID-19 on critical HIV and hepatitis services and initiatives.

Helping Adolescents Transition to Adult Care

More than one in four new HIV infections in the Asia-Pacific occur in young people aged 15–24. Continuing its commitment to helping adolescents transition to adult care, in 2019 TREAT Asia initiated plans for a study of adolescents and young adults living with HIV. A total of at least 75 HIV-disclosed adolescents with HIV are being enrolled from three participating sites in Thailand and the Philippines for initial and 12-month follow-up assessments. Critical outcomes including viral suppression, treatment adherence, pregnancy, and mortality will be assessed. Enrollment began in 2021.

Spreading the Word

IAS 2021 and Other Conferences

TREAT Asia staff and network investigators attended and presented at several regional and international conferences on HIV-related issues.

TREAT Asia had a strong presence at the 11th IAS Conference on HIV Science (IAS 2021) held virtually in July 2021. TREAT Asia Director Dr. Annette Sohn moderated a session that reviewed the evidence behind current treatments used for COVID-19 and its related conditions, and examined how therapeutics could be rapidly evaluated for COVID and other emerging infections. Dr. Sohn also co-chaired a *Journal of the International AIDS Society* special session on the critical role of implementation science in the HIV response. Numerous TREAT Asia partner investigators and affiliates gave poster presentations at the conference.




Training workshop on hepatitis B virus (HBV) and hepatitis C virus (HCV) screening, diagnosis and treatment and HIV-hepatitis co-infection

TREAT Asia also participated in: the 23rd Bangkok International Symposium on HIV Medicine in January 2021; the International AIDS Society COVID-19 Conference in February; the Conference on Retroviruses and Opportunistic Infections in March; and the sixth Asia Pacific AIDS & Co-Infections Conference in June.

Publications

In 2021 TREAT Asia continued to publish lay-language articles on HIV/AIDS research, policy, and community issues facing the Asia-Pacific as a whole. The articles and educational pieces appear on TREAT Asia's website, www.amfar.org/treat-asia/.



In September, amfAR was honored by The Elizabeth Taylor AIDS Foundation with the Elizabeth Taylor Commitment to End AIDS Award. amfAR CEO Kevin Robert Frost (right) accepted the award at a ceremony in Los Angeles.

PUBLIC INFORMATION

amfAR seeks to translate and disseminate information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences and to increase awareness and knowledge of the pandemic. amfAR publishes educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to bring the HIV epidemic to an end.

Sharing Knowledge, Building Awareness

Educational Materials


amfAR produces periodicals in both print and electronic formats, including its newsletter *Innovations*, published twice a year and distributed to about 35,000 people, and a monthly e-mail newsletter distributed to approximately 16,000 people.

The Foundation’s website—www.amfar.org—features news, interviews, and original articles covering HIV research, policy, the global epidemic, and amfAR programs and activities. The website attracts an average of 25,000 visitors per month.

amfAR creates and distributes reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public. amfAR’s Public Information team also works closely with the Public Policy Office (see above) to produce a wide range of issue briefs, facts sheets, infographics, and reports.

Epic Voices


amfAR’s *Epic Voices*, an online video series that aims to reenergize the response to HIV among millennial and LGBTQ communities, continued to generate significant engagement throughout the year. *Epic Voices* won the award for Best Video Storytelling at the 2021 PRNEWS CSR & Nonprofit Awards. Launched in 2017, the goals of the campaign are to: renew awareness of the persistent threat of HIV, underscore the urgent need to support HIV research, and support amfAR’s leadership in the search for a cure. amfAR spoke to HIV activists across the country and asked them to share their unique journeys, their insights on living with HIV, and the bold steps they have taken in the fight against the epidemic.



amfAR’s *Epic Voices* video series won the award for Best Video Storytelling at the 2021 CSR & Diversity Virtual Awards Gala.

Social Media

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation has expanded its social platforms to include TikTok, targeting the new generation of advocates. amfAR regularly updates its social channels with the latest research breakthroughs and policy news, as well as detailed coverage from its world-famous galas. amfAR has over 78,000 likes on Facebook, more than 43,000 Twitter followers, over 116,000 TikTok followers, and 170,000 Instagram followers.



Media Outreach

In FY2021, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV-related press coverage. Articles and reports involving amfAR—many of which included interviews with staff—were carried in numerous media outlets, including ABC News, NBC News, CNN, Associated Press, Reuters, *The New York Times*, *USA Today*, *U.S. News & World Report*, *Vanity Fair*, *Vogue*, *People*, *Variety*, *POZ*, *Women's Wear Daily*, *Us Weekly*, *The Hollywood Reporter*, *Deadline*, *Yahoo*, *Page Six*, *Daily Mail*, *The Daily Beast*, and *The Hill*.

Celebrity Support

amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR's Founding International Chairman, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing support of celebrities from all over the world.

Celebrity supporters in 2021 included Maria Bakalova, Jordan Barrett, Swizz Beatz, Derek Blasberg, Orlando Bloom, Ian

Bohen, Nicholas Braun, Rachel Brosnahan, Cindy Bruna, Kelly Clarkson, Glenn Close, Darren Criss, Olivia Culpo, Lee Daniels, Diplo, Nina Dobrev, Jay Ellis, Cynthia Erivo, Morgan Freeman, Emily Hampshire, Jeremy O. Harris, Emile Hirsch, Tyler Hoechlin, Julianne Hough, Magic Johnson, Alicia Keys, Regina King, Heidi Klum, Nathan Lane, Spike Lee, Julian Lennon, Julianna Margulies, Ava Max, Stella Maxwell, Bette Midler, Catherine O'Hara, Rita Ora, Dylan Penn, Jeremy Piven, Natasha Poly, Billy Porter, Julia Roberts, Michaela Jaé Rodriguez, Carine Roitfeld, Nicole Scherzinger, Nina Senicar, Sharon Stone, Bella Thorne, Ellen von Unwerth, and Lydia West.

The COVID Crisis

When the COVID-19 crisis emerged in early 2020, amfAR dedicated a section of its website to information on the coronavirus and the intersection of HIV and COVID-19 in particular. The section featured resources for people living with HIV and news of the latest studies as more and more data emerged. Audiovisual content included a series of interviews—*Connections: COVID-19 and HIV*—featuring individuals living with HIV sharing their personal experiences during the COVID-19 pandemic. The informative series garnered tens of thousands of views.

In May 2021 amfAR received the award for Outstanding Digital Theater, Individual Production, at the 87th Drama League Awards for *The Great Work Begins: Scenes from Angels in America*. amfAR and director Ellie Heyman came together in 2020 to produce the virtual performance inspired by the iconic Tony Kushner play to benefit the amfAR Fund to Fight COVID-19.

Public Information also assisted in the production of innovative virtual benefit events including *A Gala for Our Time* and *It's A Sin: A Conversation* in March 2021, and *From the Studio Part II*, an online art auction in partnership with Christie's in July 2021, as well as fundraising galas that were held in person in Cannes, France, in July 2021, and Venice, Italy, in September.



Glenn Close and Dr. Anthony Fauci were honored with amfAR's Award of Courage for their contributions to the fight against HIV and COVID-19 at amfAR's virtual Gala for Our Time in March.

GRANTS / FELLOWSHIPS / AWARDS

2021 RESEARCH GRANTS AND FELLOWSHIPS

All projects below were awarded funding during the period October 1, 2020 through September 30, 2021.

¹Supported in part with funds provided by the FAIR Foundation

TARGET GRANTS

Combination bFAb and CART cell control of persistent HIV

Principal Investigator: Todd M. Allen, PhD
Ragon Institute of MGH, MIT and Harvard
Charlestown, MA
\$200,000¹

CAR-iNKT cell immunotherapy for the treatment of HIV infection

Principal Investigator: Anastasios Karadimitris, PhD, MRCP, FRCPath
Imperial College, London
London, United Kingdom
\$192,306

Epigenetic engineering of HIV infected cells to increase the effect of CRISPR/cas9 on the hidden HIV reservoir

Principal Investigator: Jori Symons, PhD
University Medical Center Utrecht
Utrecht, Netherlands
\$199,951

The effect of natural killer cell-based therapies on the HIV reservoir

Principal Investigator: Jerome Zack, PhD
University of California, Los Angeles
Los Angeles, CA
\$200,000

MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH

Development of novel immuno-focusing strategies for HIV Env immunogens

Krim Fellow: Aleksandar Antanasijevic, PhD
Mentor: Andrew Ward, PhD
The Scripps Research Institute
La Jolla, CA
\$150,000

Probing HIV latency using pooled CRISPR-Cas9 screens in primary human CD4+ T cells

Krim Fellow: Ujjwal Rathore, PhD
Mentor: Alexander Marson, MD, PhD
Gladstone Institutes
San Francisco, CA
\$150,000

HIV-1 fusion studied by parallel single-molecule FRET and cryo-electron tomography (Krim Phase 2 grant)

Principal Investigator: Maolin Lu, PhD
University of Texas Health Science Center at Tyler
Tyler, TX
\$80,000

amfAR FUND TO FIGHT COVID-19

Symptoms and biomarkers of long COVID in people living with HIV

Principal Investigator: Annukka Antar, MD, PhD
Johns Hopkins University
Baltimore, MD
\$550,000

The impact of COVID-19 on proviral landscape of ART-treated individuals

Principal Investigator: Mathias Lichterfeld, MD, PhD
Massachusetts General Hospital
Boston, MA
\$146,597



2021 TREAT ASIA GRANTS AND AWARDS

All projects listed below were awarded funding for the period October 1, 2020, through September 30, 2021.

¹Supported by U.S. National Institutes of Health federal award number U01AI069907, with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Cancer Institute, the National Institute of Mental Health and the Fogarty International Center.

²Supported by U.S. National Institutes of Health federal award number D43TW011302, funded by the Fogarty International Center and the National Institute of Mental Health.

³Supported with funds provided by ViiV Healthcare.

AUSTRALIA

University of New South Wales

Sydney
Matthew G. Law, PhD
leDEA Asia-Pacific Research Collaboration: Data Management and Analysis Center
\$494,813¹

AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) SITES

O'Brien Street Practice

Adelaide
William Donohue, MBBS
\$1,275 (Project Year 15)

Clinic 87, Sunshine Coast Hospital and Health Service

Birtinya
David Sowden, MBBS
\$7,500 (Project Year 15)¹; \$7,350 (Project Year 16)¹

Sexual Health and HIV Service In Metro North Brisbane

Diane Rowling, MBBS, MTH, F(PHM), RACP, FACHSHM
\$7,500 (Project Year 15)¹

Julian Langton-Lockton, MBBS, FACHSHM
\$6,675 (Project Year 16)¹

Cairns and Hinterland Hospital and Health Service (CHHHS)

Cairns
Darren Russell, MD
\$7,500 (Project Year 16)¹; \$7,500 (Project Year 15)¹

RPA Sexual Health, Sydney Local Health District Camperdown

David Templeton, PhD
\$7,425 (Project Year 15)¹; \$7,125 (Project Year 16)¹

Melbourne Sexual Health Centre

Carlton
Richard Teague, MBBS, FRACGP, FRACHSHM
\$5,475 (Project Year 15)¹; \$4,875 (Project Year 16)¹

Monash Medical Centre

Clayton
Ian Woolley, MBBS, FRACP
\$7,500 (Project Year 15)¹; \$7,500 (Project Year 16)¹

D.A. Ellis Pty., Ltd.

Coffs Harbour
David Ellis, MBBS
\$450 (Project Year 15)

Clinic 34, Northern Territory, Dept of Health

Darwin
Manoji Gunathilake, MBBS, MD, FACHSHM
\$2,100 (Project Year 15)

Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic

Katoomba
Eva Jackson, MBBS, FACHSHM
\$1,950 (Project Year 15)

Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic

Kingswood
Eva Jackson, MBBS, FACHSHM
\$1,950 (Project Year 15)

Lismore Sexual Health and AIDS Services (SHAIDS), Northern NSW Local Health District

Lismore
David Smith, MBBS, DipVen, FACHSHM, GrapDip BA
\$7,500 (Project Year 15)¹; \$7,500 (Project Year 16)¹

Victorian HIV Service, Department of Infectious Diseases, The Alfred Hospital

Melbourne
Jennifer Hoy, MBBS
\$7,500 (Project Year 15)¹; \$7,500 (Project Year 16)¹

Northside Clinic (Vic) Pty Ltd

North Fitzroy
Richard Moore, MBBS
\$7,500 (Project Year 15)¹; \$7,500 (Project Year 16)¹

Prahran Market Clinic Pty Ltd

Prahran
Norman Roth, MBBS, FACHSHM
\$7,350 (Project Year 15)¹; \$7,500 (Project Year 16)¹

Gold Coast Hospital and Health Service

Southport
Caroline Thng, MBBS, MRCP
\$7,500 (Project Year 16)¹

East Sydney Doctors

Sydney
David Baker, MB, ChB, Dip Med (Sexual Health), DCH
\$6,075 (Project Year 15)¹; \$5,700 (Project Year 16)¹

Holdsworth House Medical Practice

Sydney
Mark Bloch, MD
\$7,500 (Project Year 15)¹; \$7,500 (Project Year 16)¹

St. Vincent's Hospital Sydney Limited ABN 77 054 038 872

Sydney
Andrew Carr, MD
\$7,500 (Project Year 15)¹; \$7,500 (Project Year 16)¹

Sydney Sexual Health Centre, Sydney Hospital

Sydney
Rick Varma, MBBS, MRCP
\$6,300 (Project Year 15)¹

Taylor Square Private Clinic

Sydney
Robert Finlayson, FACHSHM, DipVen, MBBS
\$6,525 (Project Year 15)¹; \$5,550 (Project Year 16)¹

Clinic 468, HNE Sexual Health, Hunter New England Local Health District

Tamworth
Nathan Ryder, MD
\$1,650 (Project Year 15)

Illawarra Shoalhaven Local Health District

Warrawong
Katherine Brown, MD
\$1,725 (Project Year 15)

Western Sydney Local Health District

Westmead
Rohan Bopage, MBBS, FRACP, MMed STD/HIV, FACHSHM
\$3,300 (Project Year 16)¹

CAMBODIA

National Center for HIV/AIDS, Dermatology & STDS / Cambodia National Institute of Public Health

Phnom Penh
Ly Penh Sun, MD, MSc; Vohith Khol, MD, MSc
TREAT Asia HIV Observational Database (TAHOD)
\$20,800¹

TREAT Asia Pediatric HIV Observational Database (TAPHOD)
\$25,000¹

Ngauv Bora, MD, MPH
CHIMERA ISR Pilot Study: Feasibility and acceptability of mental health screening and linkage to care in urban HIV clinical setting in Cambodia
\$8,000²

Mengsomanythd Chhay, MD, MPH
CHIMERA ISR Pilot Study: Assessing policy and health systems barriers and facilitators to the integration of mental health screening and linkage of care into HIV services in Cambodia
\$8,000²

CHINA

[Queen Elizabeth Hospital](#)
Hong Kong
Man Po Lee, MBBS
TREAT Asia HIV Observational Database (TAHOD)
\$22,800¹

INDIA

[The Voluntary Health Services, VHS Infectious Diseases Medical Centre](#)
Chennai
Nagalingeswaran Kumarasamy, MD, MBBS, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$22,800¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$4,000¹

[BJ Medical College & Sassoon General Hospitals](#)
Pune
Rohidas Borse, MD, MBBS
TREAT Asia HIV Observational Database (TAHOD)
\$22,200¹

leDEA Sentinel Research Network (SRN)—Asia-Pacific
\$72,675¹

Aarti Kinikar, MD, DCH, DNB, MRCP- Pediatrics UK
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$4,000¹

[Institute of Infectious Diseases](#)
Pune
Sanjay Pujari, MD, AAHIVS, MBBS
TREAT Asia HIV Observational Database (TAHOD)
\$22,300¹

INDONESIA

[Hasan Sadikin General Hospital](#)
Bandung
Anggraini Alam, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$8,500¹

[Sanglah Hospital, Udayana University School of Medicine](#)
Denpasar
I Ketut Agus Somia, SpPD, KPTI, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$22,800¹

Ketut Dewi Kumara Wati, MD, PhD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$8,500¹

[Cipto Mangunkusumo General Hospital](#)
Jakarta
Nia Kurniati, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$8,500¹

Evy Yuniastuti, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$23,000¹

[Yayasan Peduli Hati Bangsa](#)
Pagedangan
Claudius Novchovick Mone Iye
Establishment of community treatment observatory as a model for providing and improving HIV & HCV service delivery
\$12,720³

JAPAN

[National Center for Global Health and Medicine](#)
Tokyo
Junko Tanuma, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$16,640¹

KOREA

[University-Industry Foundation, Yonsei University Health System](#)
Seoul
Jun Yong Choi, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$17,640¹

MALAYSIA

[University of Malaya Medical Center](#)
Kuala Lumpur
Raja Iskandar Shah Raja Azwa, FRCP, Dip HIV, MBChB
TREAT Asia HIV Observational Database (TAHOD)
\$22,500¹

[University of Malaya](#)
Kuala Lumpur
Meng Li Chong
CHIMERA ISR Pilot Study: Facilitators and barriers to the integration of depression and substance use screening and linkage to care into the infectious diseases clinic of a tertiary-care hospital in Malaysia
\$12,000²

Pui Li Wong, MD
CHIMERA ISR Pilot Study: Facilitators and barriers to the integration of screening for HIV-associated neurocognitive disorders in routine clinical care among people living with HIV at a tertiary care center in Malaysia
\$12,000²

[Sungai Buloh Hospital](#)
Sungai Buloh
Yasmin Mohamed Gani, MD
TREAT Asia HIV Observational Database (TAHOD)
\$21,260¹

PHILIPPINES

[Research Institute for Tropical Medicine](#)
Muntinlupa City
Rossana Ditangco, MD
TREAT Asia HIV Observational Database (TAHOD)
\$22,300¹

Timothy Dizon, MD, MBA
CHIMERA ISR Pilot Study: Assessing the acceptability of an integrated telebehavioral health system in primary HIV care settings in the Philippines
\$8,000²

Anna Maureen Dungca-Lorilla, MD
CHIMERA ISR Pilot Study: Assessing the acceptability and feasibility of a collaborative care model for depression and anxiety that utilizes lay HIV counselors as case managers in primary HIV clinics in the Philippines
\$8,000²

SINGAPORE

[Tan Tock Seng Hospital](#)
Singapore
Oon Tek Ng, MBBS, MRCP, MMed, MPH
TREAT Asia HIV Observational Database (TAHOD)
\$18,200¹

TAIWAN

[Taipei Veterans General Hospital](#)
Taipei
Yu-Jiun Chan, MD
TREAT Asia HIV Observational Database (TAHOD)
\$24,800¹

THAILAND

[Chulalongkorn University](#)
Bangkok
Thanyawee Puthanakit, MD
Thai Program to Actively follow Perinatal Adolescents and Young Adults living with HIV (Thai-PAPAYA)
\$30,087³

Adolescent and Young Adult network of leDEA (AYANI) Supplement
\$2,160¹

Wipaporn Natalie Songtaweasin, MBBS, DTMH
CHIMERA ISR Pilot Study: Implementation of a collaborative care model to screen and treat depression among adolescents and young adults ages 16–24 years seeking HIV treatment and prevention services in Bangkok, Thailand
\$8,000²

[HIV-NAT / Thai Red Cross AIDS Research Centre](#)
Bangkok
Anchalee Avihingsanon, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$24,300¹

Kiat Ruxrungtham, MD, MSc
Thailand National Health Registries Study
\$19,000¹

[Institute of HIV Research and Innovation \(IHRI\)](#)
Bangkok
Nittaya Phanuphak, MD, PhD

Amphetamine-type stimulant use, HIV incidence, and ART adherence among Thai MSM and transgender women
\$76,902¹

Anal HPV and risk for anal high-grade squamous intraepithelial lesion among Thai MSM with acute HIV infection
\$78,268¹

Transgender Cohort Data Framework Development (15)
\$19,961¹

Anal HSIL screening algorithm optimization study
\$25,650¹

Asia Transgender Cohort Study
\$16,418¹

Rena Janamnuysook
CHIMERA ISR Pilot Study: Implementation of a peer-led depression screening intervention at a transgender health clinic in Thailand
\$8,000²

Mahidol University Faculty of Medicine, Siriraj Hospital
Bangkok
Supattra Rungmaitree, MD
Thai Program to Actively follow Perinatal Adolescents and Young Adults living with HIV (Thai-PAPAYA)
\$25,073³

Ramathibodi Hospital, Mahidol University
Bangkok
Sasisopin Kiertiburanakul, MD, MHS
TREAT Asia HIV Observational Database (TAHOD)
\$22,800¹

Chiang Mai University - Research Institute for Health Sciences
Chiang Mai
Linda Aupibul, MD
Thai Program to Actively follow Perinatal Adolescents and Young Adults living with HIV (Thai-PAPAYA)
\$47,608³

Thai Program to Actively follow Perinatal Adolescents and Young Adults living with HIV (Thai-PAPAYA) Coordinating Center
\$6,622¹

Romanee Chaiwarith, MD, MHS
TREAT Asia HIV Observational Database (TAHOD)
\$23,800¹

Tavitiya Sudjaritruk, MD, ScM, PhD
Adolescent and Young Adult network of leDEA (AYANI) Study
\$17,967¹

Chiangrai Prachanukroh Hospital
Chiang Rai
Suwimon Khusuwan, MD
TREAT Asia HIV Observational Database (TAHOD)
\$23,500¹

Pradthana Ounchanum, MD
Thai Program to Actively follow Perinatal Adolescents and Young Adults living with HIV (Thai-PAPAYA)
\$30,582³

Rainbow Sky Association of Thailand
Huamark, Bangkok
Phubet (Kao) Panpet
Asia Transgender Cohort Study
\$7,539¹

Srinagarind Hospital, Khon Kaen University
Khon Kaen
Pagakrong Lumbiganon, MD
Thai Program to Actively follow Perinatal Adolescents and Young Adults living with HIV (Thai-PAPAYA)
\$30,482³

Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia (Supplement)
\$500¹

USA

Johns Hopkins University
Baltimore, MD
Amita Gupta, MD, MHA
A study to evaluate the markers of lung impairment in HIV-TB coinfecting Indian adults
\$20,791¹

leDEA Asia-Pacific: JHU/BJGMC cohort and substudies
\$184,300¹

Columbia University
New York, NY
Milton Wainberg, MD
Capacity development for HIV and mental health research in Asia (CHIMERA)
\$47,753²

VIETNAM

Bach Mai Hospital
Hanoi
Do Duy Cuong, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$22,300¹

National Hospital of Pediatrics
Hanoi
Nguyen Van Lam, MD, MSc
TREAT Asia Pediatric HIV Observational Database (TAPHOD)
\$20,000¹

National Hospital of Tropical Diseases
Hanoi
Thach Ngoc Pham, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$22,300¹

leDEA Tuberculosis Sentinel Research Network (TB-SRN) study
\$24,656¹

Children's Hospital 1
Ho Chi Minh City
Du Tuan Quy, MD
TREAT Asia Pediatric HIV Observational Database (TAPHOD)
\$20,000¹

Children's Hospital 2
Ho Chi Minh City
Do Chau Viet, MD
TREAT Asia Pediatric HIV Observational Database (TAPHOD)
\$20,000¹

2021 PUBLIC POLICY GRANTS AND AWARDS

The projects listed below were awarded funding during the period October 1, 2020 through September 30, 2021.

¹Supported with funds provided by the Elton John AIDS Foundation

²Supported with funds provided by ViiV Health Care

Improving Trans Inclusion in National Strategic Plans for HIV/AIDS
Project Director: Erika Castellanos
Global Action for Trans Equality (GATE, Inc.)
New York, NY
\$155,612¹


KPIF Zambia – Building community power and sustaining impact of KPIF in Zambia
Project Director: Justine MacWilliam
AIDS Vaccine Advocacy Coalition (AVAC)
New York, NY
\$174,943²

Accountability for Kenya's Key Populations through Community Led Monitoring
Project Director: Maureen Milanga
Health GAP (Global Access Project)
Brooklyn, NY
\$199,997

2021 COMMUNITY OUTREACH AWARD


Timothy Ray Brown, The Berlin Patient: Memorial Campaign
Project Director: Jim McBride
Tides Center
San Francisco, CA
\$1,000

FINANCIALS



EXPENSES

Program	\$	20,195,486
Fundraising		4,953,774
Management and general		2,317,503
Total		\$ 27,466,763



PROGRAM EXPENSES

Research	\$	10,940,454
TREAT Asia		4,446,646
Public Policy		1,722,629
Public Information		3,085,757
Total		\$ 20,195,486

FINANCIAL HIGHLIGHTS

For the year ended September 30, 2021

Public Support and Revenue		
Public support	\$	5,015,132
Special events		2,549,655
Planned giving		2,199,353
Government funding		7,809,988
PPP loan forgiveness & funding		3,321,294
Investment income and other revenue		3,545,726
Total public support and revenue	\$	24,441,148
Expenses		
Research	\$	10,940,454
TREAT Asia		4,446,646
Public Policy		1,722,629
Public Information		3,085,757
Total program services	\$	20,195,486
Fundraising		4,953,774
Management and general		2,317,503
Total supporting services	\$	7,271,277
Total expenses	\$	27,466,763
Change in net assets		(3,025,615)
Net assets, beginning of year		41,645,894
Net assets, end of year	\$	38,620,279

STATEMENT OF FINANCIAL POSITION

Assets		
Cash and investments	\$	43,703,858
Pledges and receivables, net		6,215,620
Prepaid expenses and other assets		3,432,491
Furniture, equipment, and leasehold improvements, net		2,491,626
Total Assets	\$	55,843,595
Liabilities		
Accounts payable and accrued expenses	\$	2,834,273
Line of credit		3,509,082
Grants and fellowships payable, net		1,246,435
Deferred support and refundable advances		7,916,273
Other long-term liabilities		1,717,253
Total liabilities	\$	17,223,316
Net assets		
Net assets beginning of year	\$	41,175,319
Designation for specific operating purposes		470,575
Change in net assets		(3,025,615)
Net assets end of year	\$	38,620,279
Total liabilities and net assets	\$	55,843,595

BOARD OF TRUSTEES

Fiscal Year 2021

Co-Chair
T. Ryan Greenawalt
Managing Director
Ramirez & Co.
Los Angeles, CA

Co-Chair
Kevin McClatchy
Chairman of the Board
The McClatchy Company
Ligonier, PA

Secretary
Jay Ellis
Jay Ellis Foundation
Los Angeles, CA

Treasurer
Donald Dye
Chairman, Sky Lake Partners
New York, NY

TRUSTEES

Danielle Alexandra
CEO, London Film and Television Group
Business Ambassador, Film, Television and
Global Digital New Media
Los Angeles, CA

Amy Andelson
Screenwriter/Author
Los Angeles, CA

David Bohnett
Chairman
David Bohnett Foundation
Beverly Hills, CA

Aileen Getty
The Aileen Getty Foundation
Reno, NV

Glenn Isaacson
President
Bradford Allen
New York, NY

Michael Lorber
Senior Vice President
Douglas Elliman Real Estate
New York, NY

Larry Milstein
Co-Founder, PRZM
New York, NY

Billy Porter
Actor/Activist
New York, NY

Vincent Roberti
Chairman
Roberti Global
Washington, DC

Raymond F. Schinazi, PhD, DSc
Frances Winship Walters Professor
Emory University School of Medicine
Atlanta, GA

Jeffrey Schoenfeld
Partner
Head of Global Institutional Business
Development & Relationship Management
Brown Brothers Harriman
New York, NY

Mervyn F. Silverman, M.D., M.P.H.
President
Mervyn F. Silverman Associates
Crockett, CA

Mario Stevenson, Ph.D.
Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami
Leonard M. Miller School of Medicine
Miami, FL

Robert L. Traynham II, Ph.D.
Head of Public Affairs
Facebook
Washington, DC

Phill Wilson
Founder and CEO
Black AIDS Institute (retired)
Los Angeles, CA

TRUSTEE EMERITUS

Arthur J. Ammann, M.D. (d. 8/15/21)
President, Global Strategies for HIV Prevention
Clinical Professor of Pediatrics
University of California, San Francisco
San Francisco, CA

IN MEMORIAM

Mathilde Krim, Ph.D.
Founding Chairman

Dame Elizabeth Taylor
Founding International Chairman

Arlen H. Andelson
Sheldon W. Andelson, Esq.
Arnold W. Klein, M.D.
Mrs. Albert D. Lasker
Jonathan M. Mann, M.D., M.P.H.
Maxine Mesinger
Pauline Phillips
Natasha Richardson
Allan Rosenfield, M.D.
Peter Scott, Esq.
Wallace Sheft, C.P.A.
Tom Stoddard
Joel D. Weisman, D.O.

SCIENTIFIC ADVISORY COMMITTEE

*Adjunct Member

Jintanat Ananworanich, M.D., Ph.D.
Senior Director, Clinical Development,
Infectious Diseases
Moderna

Beau Ances, M.D., Ph.D.*
Daniel J. Brennan, MD Professor of Neurology
Washington University School of Medicine

Jane Anderson, CBE, BSc, MBBS, PhD, FRCP, FRSA, SFFMLM*
Professor
Consultant Physician
Jonathan Mann Centre / Centre for the Study of
Sexual Health and HIV
Homerton University Hospital NHS Foundation

Aleksandar Antanasijevic, Ph.D.*
Postdoctoral Research Associate
The Scripps Research Institute

Robert Arduino, M.D.*
Professor
Department of Medicine-Infectious Diseases
University of Texas Health Science Center at
Houston

Andrew Badley, M.D.*
Professor of Medicine
Mayo Clinic College of Medicine

Ben Berkhout, Ph.D.*
Professor
Department of Medical Microbiology
Academic Medical Center of the University of
Amsterdam

Pascal Bessong, Ph.D.*
Professor of Microbiology and Global Health
Chair of the HIV/AIDS & Global Health Research
Programme
University of Venda

Jason Brenchley, Ph.D.*
Senior Investigator
Immunopathogenesis Section
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

Zabrina Brumme, Ph.D.*
Professor, CIHR New Investigator, MSFHR Scholar
Faculty of Health Sciences
Simon Fraser University

Hildegard Büning, Dr. rer. nat. (Ph.D.)*
Deputy Director and Research Group Leader
Institute of Experimental Hematology
Hannover Medical School

Dennis R. Burton, Ph.D.
Professor
Department of Immunology
The Scripps Research Institute

Salvatore T. Butera, D.V.M., Ph.D.
Chief Science Officer
Scripps CHAVI-ID
The Scripps Research Institute

Cheryl Cameron, Ph.D.*
Assistant Professor
Case Western Reserve University

Edward Campbell, Ph.D.
Assistant Professor
Department of Microbiology and Immunology
School of Medicine
Loyola University at Chicago

Alex Carballo-Diequez, Ph.D.
Co-Director and Senior Research Scientist
HIV Center for Clinical and Behavioral Studies
New York State Psychiatric Institute
Columbia University

Ann Chahroudi, M.D., Ph.D.*
Associate Director, Clinical Affairs
Medical Scientist Training Program
Associate Professor, Infectious Disease
Department of Pediatrics
School of Medicine
Emory University

Nicolas Chomont, Ph.D.*
Associate Research Professor
Department of Microbiology and Immunology
Université de Montréal
Centre de Recherche du CHUM

Amy Chung, Ph.D.*
Laboratory Head
University of Melbourne

David B. Clifford, M.D.
Professor
Department of Neurology
Washington University School of Medicine

C. Budd Colby, Ph.D.
Principal
Colby Biomedical Ventures

Grant Colfax, M.D.
Director
Marin Health and Human Services
San Rafael, California

Deborah Jean Cotton, M.D., M.P.H.
Professor of Medicine
Boston University School of Medicine

Bryan R. Cullen, Ph.D., D.Sc.
James B. Duke Professor
Department of Molecular Genetics and Microbiology
Director, Duke University Center for Virology
Duke University Medical Center

Susanna Cunningham-Rundles, Ph.D.
Professor Emerita of Research Immunology
Department of Pediatrics
Weill Cornell Medical College

Richard Thomas D'Aquila, M.D.
The Howard Taylor Ricketts Professor of Medicine
Division of Infectious Diseases
Director, Northwestern HIV Translational Research Center
Feinberg School of Medicine
Northwestern University

Miles Davenport, D.Phil.*
Professor
Centre for Vascular Research
University of New South Wales

Zeger Debyser, M.D., Ph.D.*
Professor
Department of Molecular Medicine
Katholieke Universiteit Leuven

Bruno De Geest, Ph.D.
Chemical Engineer
Laboratory of Pharmaceutical Technology
Ghent University Hospital

Sherry Deren, Ph.D.
Co-Director
Center for Drug Use and HIV Research
New York University College of Nursing

Roger Detels, M.D., M.S.
Professor of Epidemiology
School of Public Health
University of California, Los Angeles

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS (DAIDS)
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Dario Diletnia, Ph.D.*
Research Assistant Professor
Pathology / Yerkes National Primate Research Center at Emory Vaccine Center
Emory University

Ivan D'Orso, Ph.D.*
Associate Professor
Department of Microbiology
University of Texas Southwestern

Daniel C. Douek, M.D., Ph.D.
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

D. Peter Drotman, M.D., M.P.H.
Editor-in-Chief
Emerging Infectious Diseases
Centers for Disease Control and Prevention

Anke A. Ehrhardt, Ph.D.
Director
Division of Gender, Sexuality, & Health
Program for the Study of LGBT Health
NYS Psychiatric Institute/Columbia University

Jacob Estes, Ph.D.*
Professor
Vaccine and Gene Therapy Institute
Division of Pathobiology & Immunology
Oregon Health and Science University

Homayoon Farzadegan, Ph.D.
Professor
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health

Maurizio Federico, Ph.D.*
Director
National AIDS Center
Division of Pathogenesis of Retroviruses
Istituto Superiore di Sanità

Daniel Fera, Ph.D.*
Assistant Professor
Department of Biochemistry
Swarthmore College

Dianne M. Finkelstein, Ph.D.
Professor of Biostatistics
Harvard School of Public Health
Director of the Cancer Center Biostatistics
Massachusetts General Hospital

Andrés Finzi, Ph.D.*
Associate Professor
Department of Microbiology and Immunology
Université de Montréal
Centre de Recherche du CHUM

Gerald Herbert Friedland, M.D.
Professor and Director
AIDS Care Program
Department of Internal Medicine
Yale School of Medicine

Christina Gavegnano, Ph.D.*
Assistant Professor
Laboratory of Biochemical Pharmacology
Department of Pediatrics
Emory University

Howard E. Gendelman, M.D.
Professor and Chair, Department of Pharmacology and Experimental Neuroscience
Margaret R. Larson Professor of Internal Medicine and Infectious Diseases
Director, Center for Neurodegenerative Disorders
University of Nebraska Medical Center

Marit van Gils, Ph.D.*
Associate Professor
Department of Medical Microbiology & Infection Prevention
Academic Medical Center of the University of Amsterdam

Trish Greenhalgh, OBE, FRCP, FRCGP, FMedSci*
Professor of Primary Care Health Sciences
University of Oxford

Nancy L. Haigwood, Ph.D.
Director and Senior Scientist
Division of Pathobiology and Immunology
Oregon National Primate Research Center
Oregon Health and Science University

Andrew Henderson, Ph.D.*
Professor of Medicine and Microbiology
School of Medicine
Boston University

Timothy Henrich, M.D.*
Associate Professor
School of Medicine
University of California, San Francisco

Alon Herschhorn, Ph.D.*
Assistant Professor of Medicine
Division of Infectious Diseases and International Medicine
University of Minnesota

Charles H. Hinkin, Ph.D.
Professor
Department of Psychiatry and Biobehavioral Sciences
David Geffen School of Medicine
University of California, Los Angeles

David Ho, M.D.
Scientific Director, Chief Executive Officer
Aaron Diamond AIDS Research Center

Ya-Chi Ho, M.D., Ph.D.*
Assistant Professor of Microbial Pathogenesis
and Medicine
Microbial Pathogenesis
Yale University

Thomas J. Hope, Ph.D.
Professor
Department of Cell and Molecular Biology
Feinberg School of Medicine
Northwestern University

Bonnie Howell, Ph.D.*
Executive Director
Infectious Disease and Vaccines
Merck & Co., Inc

Shiu-Lok Hu, Ph.D.
Professor
School of Pharmacy
University of Washington

Richard Jefferys
Basic Science, Vaccines, and
Cure Project Director
Treatment Action Group

R. Brad Jones, Ph.D.*
Assistant Professor of Immunology in Medicine
Graduate School of Medical Sciences
Weill Medical College of Cornell University

Fatah Kashanchi, Ph.D.*
Professor, Virology
Director of the Laboratory of Molecular Virology
George Mason University

Jonathan Karn, Ph.D.*
Director
Center for AIDS Research
Case Western Reserve University

Daniel Kaufmann, M.D.*
Professor
Department of Medicine
Université de Montréal
Centre de Recherche du CHUM

Marcus Kaul, Ph.D.*
Professor
Biomedical Sciences
University of California, Riverside

Vineet KewalRamani, Ph.D.
Chief, Model Development Section
HIV Drug Resistance Program
National Cancer Institute
National Institutes of Health

Scott Kitchen, Ph.D.
Assistant Professor of Medicine
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles

Richard Kornbluth, M.D., Ph.D.
President and Chief Scientific Officer
Multimeric Biotherapeutics, Inc.

Richard A. Koup, M.D.
Deputy Director, Vaccine Research Center
Chief, Immunology Laboratory
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

Priti Kumar, Ph.D.*
Associate Professor of Infectious Diseases and of
Microbial Pathogenesis
School of Medicine
Yale University

Daniel Kuritzkes, M.D.*
Harriet Ryan Albee Professor of Medicine
Department of Medicine
The Brigham and Women's Hospital, Inc.

Nathaniel R. Landau, Ph.D.
Professor
Department of Microbiology
New York University School of Medicine

Alan L. Landay, Ph.D.
Professor and Chairman
Department of Immunology and Microbiology
Rush-Presbyterian-St. Luke's Medical Center

Michael Lederman, M.D.
Scott R. Inkley Professor of Medicine
Associate Director, Center for AIDS Research
Case Western Reserve University

Tun-Hou Lee, D.Sc.
Professor of Virology, Emeritus
Department of Immunology and
Infectious Diseases
Harvard School of Public Health

Michael J. Leibowitz, M.D., Ph.D.
Professor, Medical Microbiology and Immunology
University of California, Davis

Robert J. Levine, M.D.
Professor of Medicine
Center for Interdisciplinary Research on AIDS
Yale University

Mathias Lichterfeld, M.D., Ph.D.*
Associate Professor of Medicine
Infectious Disease Division
Massachusetts General Hospital

Judy Lieberman, M.D., Ph.D.
Senior Investigator
Immune Disease Institute
Professor of Pediatrics
Harvard Medical School

Carine Van Lint, Ph.D.*
Professor
University of Brussels

H. Kim Lyerly, M.D.
Professor in Surgery, Immunology, Pathology
George Barth Geller Chair of Cancer Research
Director of the Center of Applied Therapeutics
Duke Cancer Institute
Duke University Medical Center

Frank Maldarelli, M.D., Ph.D.
Investigator
HIV DRP Host-Virus Interaction Branch
National Cancer Institute
National Institutes of Health

David M. Margolis, M.D.
Professor of Medicine, Microbiology and
Immunology, and Epidemiology
School of Medicine
University of North Carolina at Chapel Hill

Martin H. Markowitz, M.D.
Professor and Clinical Director
Aaron Diamond AIDS Research Center

Matthew Marsden, Ph.D.*
Assistant Professor
School of Medicine
University of California, Irvine

Javier Martinez-Picado, Ph.D.*
Catalan Institute for Research and Advanced
Studies Research Professor
AIDS Research Institute IrsiCaixa

Kenneth Hugh Mayer, M.D.
Infectious Disease Attending & Director of HIV
Prevention Research
Beth Israel Deaconess Medical Center
Professor of Medicine
Harvard Medical School
Medical Research Director, Co-Chair
The Fenway Institute/Fenway Health

Joseph M. McCune, M.D., Ph.D.
Professor of Medicine
Department of Medicine
University of California, San Francisco

Olivier Van Der Meeren, M.D.*
Research & Development
GlaxoSmithKline

Donna Mildvan, M.D.
Chief, Division of Infectious Diseases
Department of Medicine
Beth Israel Medical Center

Hoi Ping Mok, Ph.D.*
Department of Medicine
University of Cambridge

Daniela Monaco, Ph.D.*
Postdoctoral Fellow
Yerkes National Primate Research Center with
Emory Vaccine Center
Emory University

Kevin Morris, Ph.D.*
Professor
City of Hope

Jay A. Nelson, Ph.D.
Professor and Director
Vaccine and Gene Therapy Institute
Oregon Health and Science University

Douglas Nixon, M.D., Ph.D.*
Professor of Immunology in Medicine
Weill Medical College of Cornell University

Una O'Doherty, M.D., Ph.D.*
Associate Professor
Department of Pathology and Laboratory
Medicine
University of Pennsylvania

Nancy Padian, Ph.D., M.P.H.
Adjunct Professor of Epidemiology
School of Public Health
University of California, Berkeley

Savita Pahwa, M.D.
Professor of Microbiology and Immunology
Professor in Pediatrics and Medicine
Director of the Miami Center for AIDS Research
University of Miami Leonard M. Miller School of Medicine

Tristram G. Parslow, M.D., Ph.D.
William Patterson Timmie Professor and Chair
Department of Pathology and Laboratory Medicine
Emory University School of Medicine

Deborah Persaud, M.D.*
Professor
School of Medicine
Pediatrics Infectious Disease
Bloomberg School of Public Health
Microbiology and Molecular Immunology
Johns Hopkins University

Matija Peterlin, M.D.
Professor of Medicine, Microbiology and Immunology
Department of Medicine
University of California, San Francisco

Christopher Peterson, Ph.D.*
Staff Scientist
Fred Hutchinson Cancer Research Center

Lynn Pulliam, Ph.D.
Professor
Department of Laboratory Medicine and Medicine
University of California, San Francisco
Veterans Affairs Medical Center

Christina Ramirez, Ph.D.*
Professor of Biostatistics
Fielding School of Public Health
University of California, Los Angeles

Lee Ratner, M.D., Ph.D.
Professor
Department of Medicine
Washington University School of Medicine

Andrew Rice, Ph.D.
Professor
Department of Molecular Virology and Microbiology
Baylor College of Medicine

Nadia Roan, Ph.D.*
Associate Professor
Department of Urology
University of California, San Francisco

Melissa Robbiani, Ph.D.
Senior Scientist and Director of Biomedical HIV Research
Center for Biomedical Research
Population Council

Ruth M. Ruprecht, M.D., Ph.D.
Scientist, Department of Virology and Immunology
Southwest National Primate Research Center
Director, Texas Biomed AIDS Research Program
Texas Biomedical Research Institute

Timothy Schacker, M.D.*
Vice Dean for Research, Medical School
Director, Program in HIV Medicine
Director, Clinical Translational Research Services,
Clinical and Translational Science Institute (CTSI)
Professor of Medicine, Division of Infectious Diseases and International Medicine
University of Minnesota

Joshua Schiffer, M.D.*
Associate Member
Vaccine and Infectious Disease Division
Associate Member
Clinical Research Division
Fred Hutchinson Cancer Research Center

Frederick A. Schmitt, Ph.D.
Professor
Departments of Neurology, Psychiatry, and Psychology and Behavioral Science
Sanders Brown Center on Aging
University of Kentucky

Gerald Schochetman, Ph.D.
Senior Director
Diagnostics Research
Abbott Laboratories

Alex K. Shalek, Ph.D.*
Associate Professor of Chemistry
Massachusetts Institute of Technology

Alex Sigal, Ph.D.*
Group Leader, Max Planck Institute for Infection Biology
Africa Health Research Institute (AHRI)

Gail Skowron, M.D.
Professor of Medicine
Boston University School of Medicine

Ole Schmeltz Søgaard, M.D., Ph.D.
Professor
Department of Clinical Medicine - Department of Infectious Diseases
Aarhus University

Natalia Soriano-Sarabia, Ph.D.*
Assistant Professor
Department of Microbiology, Immunology and Tropical Medicine
School of Medicine and Health Sciences
The George Washington University

Leonidas Stamatatos, Ph.D.
Member
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Division
Immunology and Vaccine Development Program

Mario Stevenson, Ph.D.
Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of Medicine

David Vlahov, Ph.D., R.N.
Professor of Nursing,
Epidemiology, and Biostatistics
University of California, San Francisco

David J. Volsky, Ph.D.
Professor of Medicine and Pathology
Icahn School of Medicine at Mount Sinai
Director of Molecular Virology Laboratory
Department of Medicine
Mount Sinai St. Luke's and Roosevelt Hospitals

Angela Wahl, Ph.D.*
Assistant Professor
Division of Infectious Diseases
University of North Carolina School of Medicine

Andrew Ward, Ph.D.*
Professor
Department of Integrative Structural and Computational Biology
The Scripps Research Institute

Leor Weinberger, Ph.D.*
Senior Investigator
Virology & Immunology
Gladstone Institutes

Steven S. Witkin, Ph.D.
Professor of Immunology
Department of Obstetrics and Gynecology
Weill Cornell Medical College

Peter R. Wolfe, M.D.
Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles
Sub-Investigator
Ruane Clinical Research

Richard T. Wyatt, Ph.D.
Professor of Immunology
IAVI Center for Neutralizing Antibodies
The Scripps Research Institute

Jerome Zack, Ph.D.*
Distinguished Professor and Department Chair
Microbiology, Immunology & Molecular Genetics
University of California, Los Angeles

Anjie Zhen, Ph.D.*
Assistant Adjunct Professor
School of Medicine
University of California, Los Angeles

Gert van Zyl, Ph.D.*
Associate Professor
Division of Medical Virology
Department of Pathology
Faculty of Medicine & Health Sciences
Stellenbosch University

PROGRAM ADVISORY COUNCIL

Mervyn F. Silverman, M.D., M.P.H. (Chairman)
President
Mervyn F. Silverman Associates

Judith D. Auerbach, Ph.D.
Science & Policy Consultant, and Professor
School of Medicine
University of California, San Francisco

David Bloom, Ph.D.
Clarence James Gamble Professor of Economics
and Demography
Department of Global Health and Population
Harvard School of Public Health

Tim Brown, Ph.D.
Senior Fellow
The East-West Center

Daniel Douek, M.D., Ph.D.
Chief, Human Immunology Section
Vaccine Research Center
National Institutes of Health

Daria J. Hazuda, Ph.D.
Vice President
Scientific Affairs for Infectious Disease
Merck & Company, Inc.

Katherine Luzuriaga, M.D.
Professor
Molecular Medicine, Pediatrics and Medicine
University of Massachusetts Medical School

Kenneth H. Mayer, M.D.
Infectious Disease Attending & Director of HIV
Prevention Research
Beth Israel Deaconess Medical Center
Professor of Medicine
Harvard Medical School
Medical Research Director and Co-Chair
The Fenway Institute/Fenway Health, Boston

Jeffrey L. Sturchio, Ph.D.
Senior Associate
Global Health Policy Center
Center for Strategic and International Studies

Chairman of the Board
Friends of the Global Fight Against AIDS,
TB, and Malaria

Chairman of the Board
Corporate Council on Africa

Visiting Scholar
Institute for Applied Economics, Global Health &
the Study of Business Enterprise
Johns Hopkins University

Member, The Council on Foreign Relations

Phill Wilson
Member, amfAR Board of Trustees

Founder and Chief Executive Officer (ret.)
The Black AIDS Institute
Los Angeles

MANAGEMENT GROUP

Kevin Robert Frost
Chief Executive Officer

Anthony Ancona
Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor

Kyle Clifford
Chief Development Officer

Bradley Jensen
Chief Financial Officer

Rowena Johnston, Ph.D.
Vice President and Director, Research

Jeffrey Laurence, M.D.
Senior Scientific Consultant for Programs

Gregorio Millett, M.P.H.
Vice President and Director, Public Policy

AnnMari Shannahan
Vice President, Public Information

Annette Sohn, M.D.
Vice President and Director, TREAT Asia

amfAR, The Foundation for AIDS Research

NEW YORK
120 Wall Street, 13th Floor
New York, NY 10005-3908
(212) 806-1600 (tel)
(212) 806-1601 (fax)

WASHINGTON, D.C.
1100 Vermont Avenue, NW
Suite 600
Washington, DC 20005
(202) 331-8600 (tel)
(202) 331-8606 (fax)

BANGKOK, THAILAND
TREAT Asia
Exchange Tower
388 Sukhumvit Road, Suite 2104
Klongtoey, Bangkok 10110
Thailand
+66 (0)2 663 7561 (tel)
+66 (0)2 663 7562 (fax)

www.amfar.org



amfAR meets the BBB
Wise Giving Alliance's
Standards for Charity
Accountability.

